Company Overview and News

 
Vita Group expands skincare offering by acquiring Artisan clinic in Brisbane

2018-05-02 proactiveinvestors.com.au
Vita Group Limited (ASX:VTG) has expanded its non-invasive medical aesthetics (NIMA) portfolio by acquiring Artisan Cosmetic & Rejuvenation Clinic, located in Fortitude Valley, Brisbane.
VTG TLS

11
EU mergers and takeovers (April 3)

2018-04-03 reuters
BRUSSELS, April 3 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY UTX MCQEF KRYAF LKQ 0992 COL BGC JSWSTEEL VTG LNVGF KRYAY MQG

10
EU mergers and takeovers (March 26)

2018-03-26 reuters
BRUSSELS, March 26 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY UTX MCQEF KRYAF LKQ 0992 COL JSWSTEEL VTG LNVGF WYN KRYAY MQG

10
EU mergers and takeovers (March 23)

2018-03-23 reuters
BRUSSELS, March 23 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY UTX MCQEF KRYAF LKQ 0992 COL JSWSTEEL VTG LNVGF WYN KRYAY MQG

11
EU mergers and takeovers (March 21)

2018-03-21 reuters
BRUSSELS, March 21 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
KYGA MQBKY 500228 LNVGY YXOXY UTX MCQEF KRYAF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN KRYAY SSUMF MQG YXOXF

8
EU mergers and takeovers (March 20)

2018-03-20 reuters
BRUSSELS, March 20 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 16)

2018-03-16 reuters
BRUSSELS, March 16 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 15)

2018-03-15 reuters
BRUSSELS, March 15 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 14)

2018-03-14 reuters
BRUSSELS, March 14 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

12
EU mergers and takeovers (March 13)

2018-03-13 reuters
BRUSSELS, March 13 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
MQBKY 500228 BBU LNVGY YXOXY UTX MCQEF LKQ 0992 COL JSWSTEEL VTG LNVGF KWR WYN SSUMF MQG YXOXF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...